Thrivent Financial for Lutherans Sells 67,074 Shares of Halozyme Therapeutics, Inc. $HALO

Thrivent Financial for Lutherans cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 71.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,481 shares of the biopharmaceutical company’s stock after selling 67,074 shares during the period. Thrivent Financial for Lutherans’ holdings in Halozyme Therapeutics were worth $1,782,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clark Capital Management Group Inc. boosted its stake in Halozyme Therapeutics by 14.4% during the third quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock valued at $14,885,000 after buying an additional 25,582 shares during the last quarter. Intech Investment Management LLC boosted its stake in Halozyme Therapeutics by 46.0% during the third quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock valued at $10,903,000 after buying an additional 46,850 shares during the last quarter. Allworth Financial LP boosted its stake in Halozyme Therapeutics by 322.5% during the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after buying an additional 30,331 shares during the last quarter. ING Groep NV bought a new position in Halozyme Therapeutics during the third quarter valued at approximately $6,652,000. Finally, Element Squared LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at approximately $1,193,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Down 0.1%

NASDAQ HALO opened at $68.65 on Thursday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company has a fifty day moving average of $66.03 and a two-hundred day moving average of $68.77. The firm has a market capitalization of $8.14 billion, a price-to-earnings ratio of 24.69, a PEG ratio of 0.28 and a beta of 0.89. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same period in the prior year, the business posted $1.11 earnings per share. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 7.65 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on HALO. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Benchmark upped their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Wells Fargo & Company upped their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Morgan Stanley dropped their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $80.67.

Insider Buying and Selling at Halozyme Therapeutics

In other news, COO Cortney Caudill sold 20,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at approximately $974,014.80. This represents a 58.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director directly owned 38,498 shares in the company, valued at $2,443,853.04. This represents a 4.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 120,482 shares of company stock valued at $8,200,842 in the last quarter. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.